FDA Review Timeline Extended for NUZ-001 IND Clinical Hold
Filed with ASX · · 2 pages · English
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- Neurizon Secures Loan Against 2025 R&D Tax Rebate
- Neurizon Submits Clinical Hold Complete Response to FDA
- Positive feedback from FDA on strategy to lift clinical hold
- Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001
- Neurizon Enters Global Licensing Agreement with Elanco
Later from Neurizon Therapeutics
- NUZ-001 Shows Long-Term Safety and Efficacy Signals in OLE
- Appendix 4E and 2025 Annual Report
- R&D Tax Incentive Advance & Overseas Finding Approval
- Neurizon Raises $5m via Institutional Placement
- FDA Lifts Clinical Hold on NUZ-001
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics